We believe that the wellbeing of the patient is our number one priority and we conduct our research and develop our products with this in mind. We are committed to broadening access to regenerative medicine wherever possible.
Social responsibility is an integral part of our corporate culture and is reflected in our mission statement and values. We understand the social relevance of our work and our products; many address problems for which there are no viable substitute solutions (such as in the case of severe burns), target rare diseases and are considered orphan drugs (for epidermolysis bullosa, for example).
We are also conscious of the fact that researching and developing new products in the field of regenerative medicine is costly and that they are therefore not accessible to a large part of the population.
With this in mind, programmes ensuring access to regenerative medicine to those without sufficient means, providing support to patients with rare diseases and community schemes are a key part of our company strategy.
People in low- to middle-income countries are living increasingly longer and healthier lives thanks to medical advancements and innovation. However, further progress is needed to ensure that regenerative medicine becomes available to everyone all over the world.
At BioDan we are committed to making a difference and widening access to regenerative medicine. Promoting access to our products and therapies to communities all over the world currently lacking purchasing power or access to technology is our priority and a cornerstone of our responsible and ethical approach to business.
Many of those who benefit most from BioDan’s research and products suffer from rare diseases. For example, our ADMSC-fib allogeneic bioactive skin was approved in December 2014 by the European Commission as an orphan drug for Epidermolysis Bullosa.
Support networks for those suffering from many of these rare diseases are provided by an umbrella of patient associations, active interlocutors well aware of the problems facing those affected. We therefore work closely with them, helping to give patients a voice. We collaborate with the Spanish Federation of Rare Diseases (FEDER) and, in the case of epidermolysis bullosa, with DEBRA International and their Austria-based Selbsthilfe-Netwerk Verein.